p53 oncogene mutations in three human prostate cancer cell lines
- PMID: 8104329
- DOI: 10.1002/pros.2990230206
p53 oncogene mutations in three human prostate cancer cell lines
Abstract
p53 gene structure and chromosome 17p alleles were studied in the three human prostate cancer cell lines, LNCaP, DU-145, and PC-3. Our laboratory has two separate culture lines of the LNCaP human prostate cancer cells. One strain, LNCaP-GW, had a mutation in one of two alleles at position 273 (arg > his). This mutation could not be detected in a second strain of LNCaP, LNCaP-ATCC. Immunohistochemical staining for P53 protein in the cell lines indicated that protein overexpression in LNCaP was heterogeneous, even in clonal isolates derived from LNCaP-GW that contained the codon 273 mutation in every cell. We also performed in vitro and in vivo growth analysis to compare the LNCaP-GW and LNCaP-ATCC cells. LNCaP-GW grew more rapidly than LNCaP-ATCC in vitro. However, LNCaP-ATCC formed tumors efficiently when inoculated into nude mice, whereas LNCaP-GW formed tumors much less efficiently. Consideration must be given to the notion that some of these p53 mutations arose during in vitro passage. We also confirmed published findings with two other human prostate cancer cell lines. In DU-145, two mutations were found in the p53 gene. A mutation at codon 274 (pro > leu) and a second mutation at codon 223 (val > phe) were present. PC-3 cells were hemizygous for chromosome 17p. The single copy of the p53 gene had a base pair deletion at codon 138 that generated a frame shift and a new in-frame stop codon at position 169.
Similar articles
-
Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53.Cancer Res. 2003 May 1;63(9):2228-33. Cancer Res. 2003. PMID: 12727844
-
Chromosome 17p deletions and p53 mutations in renal cell carcinoma.Cancer Res. 1993 Jul 1;53(13):3092-7. Cancer Res. 1993. PMID: 8319216
-
p53 oncogene mutations in human prostate cancer specimens.J Urol. 1994 Feb;151(2):492-5. doi: 10.1016/s0022-5347(17)35000-0. J Urol. 1994. PMID: 7904314
-
An uncertain role for p53 gene alterations in human prostate cancers.Cancer Res. 1996 Aug 15;56(16):3814-22. Cancer Res. 1996. PMID: 8706029
-
P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.Anticancer Res. 1994 Nov-Dec;14(6B):2785-90. Anticancer Res. 1994. PMID: 7872719
Cited by
-
Monitoring Spontaneous Quiescence and Asynchronous Proliferation-Quiescence Decisions in Prostate Cancer Cells.Front Cell Dev Biol. 2021 Dec 10;9:728663. doi: 10.3389/fcell.2021.728663. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34957090 Free PMC article.
-
Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways.Prostate. 2013 May;73(7):754-62. doi: 10.1002/pros.22619. Epub 2012 Nov 28. Prostate. 2013. PMID: 23192356 Free PMC article.
-
Functional p53 determines docetaxel sensitivity in prostate cancer cells.Prostate. 2013 Mar;73(4):418-27. doi: 10.1002/pros.22583. Epub 2012 Sep 19. Prostate. 2013. PMID: 22996738 Free PMC article.
-
Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis.Cancer Sci. 2012 Jun;103(6):1090-8. doi: 10.1111/j.1349-7006.2012.02272.x. Epub 2012 Apr 15. Cancer Sci. 2012. PMID: 22417066 Free PMC article.
-
Androgen signal transduction and prostatic carcinoma.World J Urol. 1994;12(2):99-103. doi: 10.1007/BF00184245. World J Urol. 1994. PMID: 8087144 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous